Bleichroeder LP Tricida, Inc. Transaction History

Bleichroeder LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$8.51 - $13.6 $425,500 - $680,000	50,000 Added 11.11%	500,000 $5.24 Million
Q2 2022 Aug 10, 2022	SELL	$7.31 - $11.85 $5.47 Million - $8.87 Million	-748,400 Reduced 62.45%	450,000 $4.36 Million
Q1 2022 May 11, 2022	SELL	$7.35 - $10.63 $1.24 Million - $1.8 Million	-168,953 Reduced 12.36%	1,198,400 $9.85 Million
Q4 2021 Feb 10, 2022	BUY	$4.19 - $9.56 $282,209 - $643,894	67,353 Added 5.18%	1,367,353 $13.1 Million
Q3 2021 Nov 15, 2021	BUY	$3.56 - $4.64 $4.63 Million - $6.03 Million	1,300,000 New	1,300,000 $6.03 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Bleichroeder LP, based on Form 13F filings with the SEC.

Stay updated on Bleichroeder LP with notifications on news.